NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.35 -0.03 (-0.04%) GOLD FUTURES
2,323.00 -1.20 (-0.05%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
49,952.51 -748.45 (-1.48%)
Iovance Biotherapeutics, Inc. (IOVA)
After hours:
| Previous close | 13.88 |
| Open | 13.89 |
| Bid | 13.98 x 1600 |
| Ask | 14.01 x 1600 |
| Day's range | 13.53 - 14.13 |
| 52-week range | 3.21 - 18.33 |
| Volume | |
| Avg. volume | 8,957,826 |
| Market cap | 3.912B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.89 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.00 |
ZacksWatch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
ZacksIovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.
GlobeNewswireIovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or
